Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

An industry centered around unproven stem cell therapies is flourishing due to misinformation.

Why it matters: Stem cells offer a tantalizing potential to address a large number of diseases, like Parkinson's, ALS, cancers and bodily injuries. But only a small number of therapies have been found safe and effective through clinical trials, while misinformation continues to proliferate.

  • Not only are people sometimes losing tens of thousands of dollars for unproven therapies, but some have reported suffering permanent damage like blindness, pulmonary embolism or tumor growth, says Leigh Turner, associate professor at the University of Minnesota's Center for Bioethics.
  • Using unproven therapies may also exclude people from clinical trials, causing them to lose that potential treatment option, as well as damaging scientific discoveries by limiting trial participants, Turner adds.

The latest: The Pew Charitable Trusts issued a brief in early June that describes a rising number of reported adverse events.

  • There are more than 700 U.S. clinics offering unapproved stem cell and regenerative medicine interventions for conditions such as Alzheimer’s disease, muscular dystrophy, autism, spinal cord injuries and even COVID-19, Pew reports.

Background: Clinics with unregulated stem cell products or therapies began emerging in the early 2000s all over the world, "taking advantage of the media hype around stem cells and patients’ hope and desperation," says Mohamed Abou-el-Enein, executive director of the Joint USC/CHLA Cell Therapy Program at USC's Keck School of Medicine.

  • "There is an infodemic in this area; it's run by misinformation," says Zubin Master, associate professor of biomedical ethics at Mayo Clinic's Biomedical Ethics Research Program and the Center for Regenerative Medicine.
  • He points to a growing practice of using "tokens of legitimacy," where clinics try to fully legitimize their practices by having prestigious scientists on their boards or showcase figures from pay-to-participate trials, which have their own ethical dilemmas.

Regulatory agencies like the FDA need to crack down on these misinformation campaigns, several experts say.

  • The FDA established a regenerative medicine policy framework in November 2017, but it gave a long "discretion" period of three years that was extended another half year due to the pandemic, to May 31. The agency currently has only a short list of approved cellular and gene therapy products.
  • Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, tells Axios the "compliance and enforcement discretion policy was never intended to excuse the violations of manufacturers or health care providers offering unapproved regenerative medicine products that have the potential to put patients at significant risk."
  • "During that three and a half year period, we did take compliance and enforcement actions to protect the public health," Marks said in an email. Some believe the FDA will crack down now that the discretion period is over.

What they're saying: Turner says in that period the FDA contacted about 400 businesses to warn of noncompliance and issued several warning letters, but adds that was "probably of very little consequence. ... A one-year period could be justified, but three years is basically like a security guard walking away from the post, and you can guess what's going to happen."

  • Abou-el-Enein says, "I think FDA has established an excellent regulatory system for cell therapy development ... [but] it is understandably challenging to keep the regulations up to speed."

The big picture: This is a global threat as well, Master and Abou-el-Enein say. In a recent perspective in the journal Stem Cell Reports, they argue for the WHO to establish an expert advisory committee to explore global standards.

  • "We need to devise new approaches to rally governments, regulators, and local communities to support the growing efforts to curb the spread of unproven SCIs," or stem cell interventions, Abou-el-Enein says.
  • The 2021 guidelines from the International Society for Stem Cell Research have also stressed the need for standards, they say.

What's next: Researchers are still hopeful stem cell therapies can be effective but emphasize the need for more research into how stem cells work and how they can be manipulated for therapies.

  • There have been some promising results from cell-based therapy R&D via academic and biotech firms that either has or is currently undergoing proper clinical testing protocols, Abou-el-Enein says, pointing to the EU's authorization of a treatment for Crohn's disease called Alofisel and Holocar for corneal ulcers.
  • "We’ve seen improbable advances in the field of cell-based regenerative medicine that show great promise. The advances in cell-based gene therapy indicate what may be possible, as evidenced by the five FDA-approved chimeric antigen receptor-T cell therapies," Marks says.

Go deeper

Proteins give a clearer picture of cancer growth

Illustration: Rebecca Zisser/Axios

A new analysis found unique networks of hundreds of proteins that may drive the growth of breast, head and neck cancers, according to three studies out today.

Why it matters: Cancers differ in many aspects, including their mutations. But, there are some common systems of cells involved, including protein networks, that may affect cancer growth and scientists hope to target them with therapies.

Updated 37 mins ago - World

State Department orders evacuation of U.S. diplomats' families from Ukraine

From left, Under Secretary for Political Affairs Victoria Nuland, Secretary of State Antony Blinken and U.S. Chargés d'Affaires in Ukraine Kristina Kvien during a meeting with Prime Minister of Ukraine Denys Shmyhal in Kyiv. Photo: Yevhen Liubimov/ Ukrinform/Barcroft Media via Getty Images

The State Department will begin evacuating families and non-essential staff from the U.S. Embassy in Kyiv this week, according to a travel advisory published Sunday evening.

Why it matters: The move underscores U.S. fears that a Russian invasion could destabilize Ukraine and threaten embassy's ability to assist Americans.

Perfect storm brewing for extreme politicians

Data: Axios research; Table: Jacque Schrag/Axios

Redistricting and a flood of departing incumbents are paving the way for more extreme candidates in this year's midterm elections.

Driving the news: At least 19 House districts in 12 states are primed to attract such candidates — hard partisans running in strongly partisan districts — according to an Axios analysis of districts as measured by the Cook Political Report's Partisan Voter Index (PVI).

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!